PRODUCTS
PROBLEM - GLIOBLASTOMA
Standardized approach
Different cancer cells survive in different ways but all patients treated in the same way
Long-term treatment
Most aggressive brain tumour.
Median survival:
15 months
95% mortality rate within 5 years
50 000 patients die
each year
Modern drug discovery has benefitted enormously from advances in human genomics. Recent publications on the druggable genome suggests that the human genome encodes at least 5000 well defined molecular drug targets. These fall into specific families of genes, such as the protein kinases, phosphodiesterases, ion-channels, and G-protein coupled receptors.

IOTA offers individually-tailored gene family-based drug discovery platforms to address the involvement of specific members of gene families in human disease.
about Glioblastoma Drug Bank

  • was created by IOTA in collaboration with the WINDOW consortium, supported by The Brain Tumour Charity (UK)
  • Contains 1025 compounds
  • that were shown effective against glioblastoma in the literature
based on the IOTA Glioblastoma Drug Bank

  • client (or IOTA on their behalf) selects an 80-compound library focused on chosen specific targets
  • IOTA supplies compounds (in 96-well plates)
  • optionally, IOTA also supplies standard cell lines for chemotyping
  • optionally, IOTA also supplies gene expression analysis of hits
  • Integrated data analysis package from the IOTA GDB

Chemotyping Analysis

  • Client chooses any compounds - up to 80
  • IOTA performs standard or patient cell line chemotyping tests, with dose-response curves detailing IC50s for each cell line
  • optionally, IOTA also supplies gene expression analysis for client
  • Integrated Chemotyping data analysis package

Drug Response Analysis

  • up to 20 compounds, either proprietary or from the IOTA GDB
  • IOTA performs chemotyping and gene expression analysis
  • IOTA details active compounds, predicts possible drug combinations and runs confirmatory synergy analyses
  • all data returned to client exclusively, or IOTA incorporates data into a proprietary drug response database for later non-exclusive licensing
  • Integrated Drug Response data analysis package
Drug Discovery Partnerships

  • client chooses a molecular target
  • IOTA performs protein expression, purification and drug screening using both FBDD and SBDD approaches
  • IOTA collaborates with commissioning company in iterative LO chemistry
  • all data belongs exclusively to client
  • Collaborative Drug Discovery Partnerships


DRUG DISCOVERy & DEVELOPMENT PARTNERSHIPS
IOTA's Drug Discovery Partnerships are designed for groups seeking to move rapidly and cost effectively from validated target to hit molecules or looking to find new hits within novel, patentable chemical space.

Whether your target has structural information or only information about existing ligands or even just low affinity fragments, IOTA's screening tools can identify lead fragments, incorporate these into novel scaffold structures, and design potent, selective, and orally bioavailable lead compounds.

For more information contact info@iotapharma.com

Modern drug discovery has benefitted enormously from advances in human genomics. Recent publications on the druggable genome suggests that the human genome encodes at least 5000 well defined molecular drug targets. These fall into specific families of genes, such as the protein kinases, phosphodiesterases, ion-channels, and G-protein coupled receptors.

IOTA offers individually-tailored gene family-based drug discovery platforms to address the involvement of specific members of gene families in human disease. An example of this is the phosphodiesterase (PDE) gene family, which has been the subject of several billion dollar drug discovery campaigns. IOTA is currently working with partners on members of the extended PDE gene family.

One major approach to gene family drug discovery is by using gene family tailored fragment sets. These can be specifically designed to initiate target-based drug discovery programmes. The role of FBDD in PDE drug discovery is the subject of recent work at IOTA.

If you are interested in gene family based drug discovery, let us know by contacting us on info@iotapharma.com